My watch list
my.bionity.com  
Login  

03-05-2012: Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a tumor-targeting alpha-pharmaceutical (also known as a Targeted Thorium Conjugate, or TTC).

Over the past 12 months, Algeta and Genzyme have jointly pursued a defined research program and both have contributed resources and expertise to the collaboration. The program and the encouraging results produced to date have been reviewed by Algeta and Sanofi (following its 2011 acquisition of Genzyme) and both parties have now decided that the collaboration should continue on the same basis for a further year.

Thomas Ramdahl, Executive Vice President and Chief Technology Officer at Algeta, said: “We have made significant progress in this collaboration with Genzyme and are delighted that it is to continue with the added antibody experience provided by the broader Sanofi team.”

Contact / Request information

Request further information free of charge:

Watchlist

This is where you can add this news to your personal favourites

Facts, background information, dossiers
More about Algeta
More about Sanofi-Aventis
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE